Biomea Fusion, Inc. (BMEA) is a leading-edge biopharmaceutical company that focuses on discovering, engineering, and developing innovative drugs aimed at curing genetic diseases with high unmet medical needs. The company is based in Redwood City, California, USA, and was founded in November 2017.
One of the unique characteristics of Biomea Fusion lies in their groundbreaking approach that uses proprietary gene editing technology to develop novel gene therapy drugs. Their mission is to create transformative gene therapies that can potentially provide definitive cures for patients suffering from severe genetic diseases.
Biomea Fusion's primary asset is BMF-219, an irreversible Menin inhibitor, a program that pursues the development of a cure for leukemia. Research, so far, shows that the inhibitor has the potential to block the protein-protein interaction between Menin and MLL fusion proteins which have been known to be a common cause for acute leukemia. Biomea Fusion is working with utmost dedication to bring BMF-219 forward as they see the vast potential of this innovative therapy to change the landscape of acute leukemia treatment.
The company is led by a highly skilled team of professionals, who carry a wealth of knowledge and experience in the fields of biotechnology and gene-editing. They persistently focus their scientific and technological prowess on engineering revolutionary drugs that may potentially reshape the common treatment methods of genetic diseases.
Biomea Fusion’s commitment to excellence, adherence to quality, and consistent strive for innovation are demonstrated through their operations and ambitious drug development projects. Furthermore, they are committed to maintaining transparency and ethically sound practices in all their research and development processes
In April 2021, Biomea Fusion went public with an initial public offering (IPO), raising approximately $120 million. This milestone attests to the company's growing reputation as a trailblazer in the field of gene-editing and drug discovery.
In conclusion, Biomea Fusion, Inc. stands out as a life sciences company that is committed to pushing the boundaries of gene therapy to alleviate the suffering of patients with serious genetic diseases. With its innovative technology and commitment to pioneering research, Biomea Fusion is paving the way towards future revolutionary treatments in medicine.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Biomea Fusion Inc. (BMEA) stock fell by over 10% after the company initially announced, then quickly terminated, an underwritten stock and warrant offering due to unfavorable market conditions. The proposed offering aimed to fund clinical-stage diabetes and obesity programs, highlighting the company's ongoing need for cash. Analysts maintain a negative outlook on the early-stage biotech due to its cash-burning nature, lack of revenue, and high valuation based on pipeline optionality, with technical indicators showing a clear short-term downtrend.
Biomea Fusion Inc (NASDAQ: BMEA) shares dropped 18.82% in after-hours trading after the company announced an underwritten public offering of its common stock and pre-funded warrants. The clinical-stage diabetes and obesity medicines company did not disclose the terms or size of the offering, which is subject to market conditions. This announcement led to the significant share price decrease despite the company's positive price trend rankings.
Biomea Fusion (NASDAQ: BMEA) shares dropped by nearly 19% after the company terminated its proposed public offering of securities. Additionally, Biomea Fusion announced a delay in the topline results from its Phase I GLP-131 trial for BMF-650, which are now expected in October 2026 instead of the previously anticipated third quarter of 2026. The company had also added an extra cohort to the study in June to further optimize its weight reduction potential.
Biomea Fusion Inc. (NASDAQ: BMEA) shares dropped 18.82% in after-hours trading after the company announced an underwritten public offering of common stock and pre-funded warrants. The clinical-stage biopharmaceutical company, which is developing therapies for diabetes and obesity, did not disclose the terms or size of the offering. Biomea Fusion intends to grant the underwriter an option to purchase an additional 15% of the total shares and warrants.